Public healthManitobaSouthern Health-Santé Sud

Southern Health launches flu campaign with 52 clinics as season begins

Southern Health-Sante Sud has launched its fall flu-shot campaign, with 52 clinics planned, as influenza season begins. Medical Officer of Health Dr. Davinder Singh says cases are low but could rise. Shots are strongly recommended for children under five, adults over 65, pregnant women, care-home residents, Indigenous people and those with chronic heart or lung conditions; all Manitobans over six months are eligible. Uptake is falling: 15 per cent of children under five were immunized last year, down from 30 per cent a few years earlier. Early lab signals point to H1N1 this winter.

Flu season hits care homes, clinics and hospitals first, and frontline workers face higher exposure while also fielding vaccine questions from patients and families. Knowing the clinic rollout and priority groups helps staff protect vulnerable patients and answer those questions.

Ask about this brief

Answers are written by AI from this brief and the original article it summarizes, and can be wrong. Check the original source before you act.

2 free questions a day without an account. Members ask as often as they like, free.

Not medical, legal or immigration advice.

Read the original

News source: Southern Health launches flu campaign with 52 clinics as season begins (opens in a new tab) — Steinbach Online

Report a problem

Public healthCanada

Viokace shortage expected from Feb 2027 to Nov 2027 due to ingredient delays

Nestle Enterprises reports its Viokace (pancrelipase) tablet faces an anticipated shortage from Feb 1, 2027, after a shortage of an active ingredient delayed finished-drug production. The shortage is estimated to end Nov 30, 2027, with an allocation process effective Nov 1, 2026.

Pancrelipase is used by people with pancreatic insufficiency, including cystic fibrosis and chronic pancreatitis — patients and pharmacies should plan supply well ahead of the February start.

Due todayPublic healthCanada

AbbVie to discontinue Humira 40 mg adalimumab on Oct 30

AbbVie reports its Humira (adalimumab) 40 mg solution for subcutaneous injection, in pre-filled syringe and pen form, is to be discontinued on Oct 30, 2026, for business reasons.

Humira is a widely used biologic for arthritis, psoriasis and inflammatory bowel disease — patients and prescribers should confirm the switch to biosimilars or other alternatives.

Due in 14 daysPublic healthCanada

Apotex's rupatadine 10 mg allergy tablets in actual shortage to Nov 13

Apotex reports its Apo-Rupatadine (rupatadine) 10 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Oct 29, 2026 and is estimated to end Nov 13, 2026.

Rupatadine is a widely used antihistamine for allergies — patients and pharmacies should check stock and alternatives while the shortage runs.